Medtronic secured approval from the US Food and Drug Administration (FDA) for its closed-loop spinal cord stimulation (SCS) device, designed to adjust stimulation in real-time, for the treatment ...

Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings ...

Medical devicemaker Medtronic has had a busy year filled with tech innovation, leadership appointments and restructuring efforts. Here are 19 updates from the company in 2024: 1. Medtronic received ...

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to ...

Market Drivers : The increasing prevalence of chronic gastrointestinal disorders, particularly gastroparesis, is a primary ...

WEDNESDAY, Nov. 20, 2024 (HealthDay News) -- Spinal cord stimulation (SCS) for treatment of chronic ... Several authors ...

Medtronic ( (MDT) ) has released its Q2 earnings. Here is a breakdown of the information Medtronic presented to its investors.Don't Miss out on ...

While earlier versions of the device provided a constant level of stimulation, Medtronic’s new product can read signals from ...

Medtronic is currently the leader in terms of market share, with Boston Scientific and Abbott also key players. The vagus nerve stimulator segment is predicted to contribute $1bn to the market in ...

On March 31, 2000, an expert FDA panel met regarding the Medtronic Activa Deep Brain Stimulator Parkinson's Control System. Upon consideration of safety concerns and expert opinion from medical ...